Trump's rates on India: What forced the US government to leave Indian Pharma out of the 50% tax rate? Explain

The Indian pharmaceutical industry is exempt from immediate tariff increases in the US due to the importance of generic medication for providing affordable healthcare in the country. This decision comes after President Trump implemented a 25% tariff on India related to the purchase of Russian oil, which brought the total tariff to 50%, which comes into effect today, August 27. According to Sudarshan Jain, Secretary General of the Indian Pharmaceutical Alliance, the Indian pharmaceutical industry “excluded from SU’s immediate rates in the US, because generic medicine is retained by SU’s immediate health care. Ani. Profit margins. Exporters are starting to move their consignments to Australia, which is expected to threaten the stability of the US Medicare system. Offer, with about half of its generic medication from India. Institutional Equity said that if it comes down to it and the pharmaceutical rates are not reversed, companies may have to significantly reduce their US portfolio (in some cases, completely abandoned other options, such as transferring the increased costs to patients. To sell it in the US, especially given the ongoing pricing. Portfolio is essentially cut, the broker believes that it can cause a domino effect, as Indian firms may need to use a more aggressive approach to follow growth in India and the EU/row, which may lead to price competition. Check out certified experts before making investment decisions.